

Orchid Pharma Limited

Regd. Office: Plot Nos. 121 – 128, 128A – 133, 138 – 151, 159 – 164, SIDCO Industrial Estate, Alathur, Chengalpattu District – 603110, Tamil Nadu, India

Ph. +91 - 44 - 2744 4471 - 78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com

CIN : L24222TN1992PLC022994

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025

(All amounts are in lakhs of Indian Rupees, unless otherwise stated)

S. No.	Particulars	Standalone financial results				Consolidated financial results			
		For the quarter ended		For the year ended		For the quarter ended			For the year ended
		June 30, 2025 (Unaudited)	Mar 31, 2025 (Audited) (Refer Note 5)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)	June 30, 2025 (Unaudited)	Mar 31, 2025 (Audited) (Refer Note 5)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
	Income from Operations								
1	Net Sales / Income from operations	17,292.88	23,747.87	24,440.61	92,192.59	17,292.88	23,747.87	24,440.61	92,192.59
2	Other Income	1,593.04	625.68	777.19	3,192.91	1,144.76	389.72	757.07	2,747.47
3	Total Income (1+2)	18,885.92	24,373.55	25,217.80	95,385.50	18,437.64	24,137.59	25,197.68	94,940.06
4	Expenses								
	Cost of materials consumed	11,015.74	13,694.46	15,277.25	58,546.06	11,015.74	13,694.46	15,277.25	58,546.06
	Changes in inventories of raw material, work-in-progress, stock-in-trade and finished goods	(1,207.99)	(17.24)	(251.81)	(4,385.11)	(1,207.99)	(17.24)	(251.81)	(4,385.11)
	Purchases of Stock in trade	78.79	124.40	-	261.31	78.79	124.40	-	261.31
	Employee benefit expenses	2,161.29	2,224.24	2,137.37	8,636.06	2,161.29	2,224.24	2,200.10	8,636.06
	Finance costs	325.75	397.96	347.34	1,454.01	325.75	391.50	349.84	1,454.01
	Depreciation and amortization expense	865.41	876.21	844.39	3,443.62	865.41	887.17	844.39	3,454.58
	Other expenses	3,827.19	4,288.65	3,953.00	16,781.21	3,827.53	4,923.65	3,965.88	17,416.67
	Total Expenses	17,066.18	21,588.68	22,307.54	84,737.16	17,066.52	22,228.18	22,385.65	85,383.58
5	Profit / (Loss) before exceptional items and tax (3-4)	1,819.74	2,784.87	2,910.26	10,648.34	1,371.12	1,909.41	2,812.03	9,556.48
6	Exceptional items	-	-	-	-	-	-	-	-
7	Profit / (Loss) before tax (5+6)	1,819.74	2,784.87	2,910.26	10,648.34	1,371.12	1,909.41	2,812.03	9,556.48
8	Tax expense								
	Current tax	-	-	-	-	-	-	-	-
	Tax adjustments of earlier years	-	-	-	-	-	6.18	(15.41)	(9.23)
	Deferred tax	-	-	-	-	-	(10.12)	-	(10.12)
	Total Tax Expenses	-	-	-	-	-	(3.94)	(15.41)	(19.35)
9	Profit / (Loss) for the period before share of profit of Associates (7-8)	1,819.74	2,784.87	2,910.26	10,648.34	1,371.12	1,913.35	2,827.44	9,575.83



Shankar

Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 (Contd...)

S. No.	Particulars	Stand alone financial results				Consolidated financial results			
		For the quarter ended		For the year ended		For the quarter ended			For the year ended
		June 30, 2025 (Unaudited)	Mar 31, 2025 (Audited) (Refer Note 5)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)	June 30, 2025 (Unaudited)	Mar 31, 2025 (Audited) (Refer Note 5)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
9	Profit / (Loss) for the period before share of profit of Associates (7-8)	1,819.74	2,784.87	2,910.26	10,648.34	1,371.12	1,913.35	2,827.44	9,575.83
10	Profit / (Loss) from discontinued operations	-	-	-	-	-	-	-	-
11	Tax expense of discontinued operations	-	-	-	-	-	-	-	-
12	Profit / (Loss) from discontinued operations (after tax) (10-11)	-	-	-	-	-	-	-	-
13	Profit / (Loss) for the period before share of profit of Associates	1,819.74	2,784.87	2,910.26	10,648.34	1,371.12	1,913.35	2,827.44	9,575.83
14	Add: Share of Profit/ (Loss) of Associates	-	-	-	-	119.94	316.11	107.62	389.85
15	Profit / (Loss) for the period (10+11)	1,819.74	2,784.87	2,910.26	10,648.34	1,491.06	2,229.46	2,935.06	9,965.68
16	Other comprehensive income, net of income tax								
17	a) (i) items that will not be reclassified to profit or loss	(15.48)	166.75	(12.44)	(75.13)	(15.48)	166.75	(12.44)	(75.13)
	(ii) income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	b) (i) items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Total other comprehensive income/ (loss), net of income tax	(15.48)	166.75	(12.44)	(75.13)	(15.48)	166.75	(12.44)	(75.13)
18	Total comprehensive income/ (Loss) for the period (12+13)	1,804.26	2,951.62	2,897.82	10,573.21	1,475.58	2,396.21	2,922.62	9,890.55
19	Paid-up equity share capital	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91	5,071.91
	Other Equity				1,27,333.00				1,21,656.63
	Face value per share (Rs)	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
20	Earnings per equity share *:								
	- Basic (Rs.)	3.59	5.49	5.74	20.99	2.94	4.40	5.79	19.65
	- Diluted (Rs.)	3.59	5.49	5.74	20.99	2.94	4.40	5.79	19.65

* * EPS for the quarters are not annualised



M. Shant

Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 (Contd...)

Notes:

- 1 The above results for the quarter and year ended June 30, 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 12, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results.
- 2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable.
- 3 99,02,705 fully paid up Equity Shares of face value ₹ 10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised.

As on June 30, 2025 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below :

Statement of QIP Net Funds raised and utilisation				
Particulars	Amount as stated in the Offer Document (Rs. in Lakhs)	Total amount utilised upto June 30, 2025 (Rs. In Lakhs)	* Balance amount as on June 30, 2025 kept in Fixed deposits (Rs. In Lakhs)	Remarks
1) Investment in OBPL (subsidiary) for setting up Jammu Manufacturing Facility	9000	6,461	2539	
2) Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	14100	14100	-	
3) Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	9982	36	9946	
4) General corporate purposes	6098	6,372	0	#
Total	39180	26969	12485	

#As per the QIP offer document the amount allocated for General Corporate Purpose (GCP) was ₹ 6098 Lakhs which was based on the proposed net proceeds after issue expenses being ₹ 39180 Lakhs. However, net proceeds transferred to Monitoring Account was ₹ 39454 Lakhs as against the proposed Net Proceeds of ₹ 39180 Lakhs, therefore the surplus amount of ₹ 274 Lakhs has been included in the GCP Balance as on 30th June 2025

* Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits.



Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 (Contd...)

- 4 The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable.
- 5 The figures for the quarter ended March 31, 2025 represents the balancing figure between the Audited results for the year ended March 31, 2025 and the published year to date figures up to the third quarter of the relevant year.
- 6 The Company has submitted a petition with the Hon'ble National Company Law Tribunal (NCLT), Chennai Bench, for amalgamation of its Holding Company, Dhanuka Laboratories Limited ("the Amalgamating Company"), with the Company in compliance with Sections 230-232 and other relevant provisions of the Companies Act, 2013. The Scheme of Amalgamation had been approved by the Board of Directors of the respective companies. Further, in compliance with the SEBI Listing Regulations and Master Circulars issued thereunder, the Company has obtained observation letters from BSE Limited and the National Stock Exchange of India Limited ("Stock Exchanges") giving their no objection to the said amalgamation.

The Hon'ble NCLT, vide its order dated 29th April 2025, inter alia, issued directions for convening meetings of the equity shareholders of the Company and the unsecured creditors of both companies, and dispensed with the meetings of the equity shareholders of the Amalgamating Company and the secured creditors of both companies, considering their respective consents to the Scheme already submitted before the Hon'ble NCLT. Subsequently, the requisite approvals of the concerned shareholders and creditors, as directed, have been duly secured. Further, the Companies submitted the Joint Company Petition seeking approval on the Scheme of Amalgamation, pursuant to which the Hon'ble NCLT admitted the petition for its consideration and sanction.

- 7 Figures of the previous period have been regrouped/reclassified /restated wherever considered necessary

Place: Gurugram
Date : August 12, 2025



Initiated for identification purposes

For and on behalf of the Board



A handwritten signature in blue ink, appearing to read "Manish Dhanuka".

Manish Dhanuka
Managing Director

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone and Consolidated Financial Results of **Orchid Pharma Limited** ("the Company") for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards ('IND AS') prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material mis-statement.



Other matter:

5. The figures for the quarter ended March 31, 2025 as reported in the Statement is the balancing figures between audited figures in respect of the full financial year ended on March 31, 2025 and the published year to date figures upto the end of the third quarter ended December 31, 2024. Also, the figures up to the end of the third quarter had only been reviewed by us as required under the Listing Regulations and not subjected to audit. Our Conclusion is not modified in respect of this matter.



Place: Mumbai
Date: August 12, 2025

For Singhi & Co.
Chartered Accountants
Firm Regn. No. 302049E

A handwritten signature in blue ink, appearing to read 'Sudesh Choraria', written over a light-colored rectangular background.

Sudesh Choraria
Partner
Membership No.204936
UDIN: 25204936BMIPCG6946

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone and Consolidated Financial Results of **Orchid Pharma Limited** (hereinafter referred to as "the Parent Company") and its subsidiaries (the Parent Company and its Subsidiaries together referred to as " the Group") and its associate for the quarter ended June 30, 2025 ("the Statement") attached herewith being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent Company's Management and has been approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to issue a conclusion on these financial results based on the review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - i) Orchid Pharmaceuticals Inc., USA
 - ii) Bexel Pharmaceuticals Inc., USA
 - iii) Diakron Pharmaceuticals, Inc. USA
 - iv) Orchid Bio-Pharma Limited



5. **Basis for Qualified Conclusion:**

We draw attention to the following:

- a) The unaudited Consolidated financial results for the quarter ended June 30, 2025 include the financial results for the quarter ended June 30, 2025 of the following subsidiary companies, accounted on a line by line consolidation method:
 - i) Orchid Pharmaceuticals Inc., USA
 - ii) Bexel Pharmaceuticals Inc., USA
 - iii) Diakron Pharmaceuticals, Inc. USA

We did not review the financial information of the above three subsidiaries whose financial statements reflect total revenue from operations of Rs. Nil, total comprehensive income after tax of Rs. Nil for the quarter ended June 30, 2025 as considered in the unaudited consolidated financial statements.

The financial information of the subsidiaries are unaudited and have been furnished to us by the management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and associate, is based solely on such unaudited financial results. Accordingly, we do not express any conclusion on the completeness and true and fair view of the financial results, including adjustments, if any, required on the carrying amount of assets and liabilities of the above subsidiaries and associate and foreign currency translation reserve as at June 30, 2025 included in the unaudited consolidated financial results. This has also been qualified in the Limited Review reports of the earlier quarters and audit reports of the earlier years, audited by us.

6. We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.
7. Based on our review conducted as above, except for the possible effects of the matters specified in Para 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matter:

8. We did not review the financial information of 1 subsidiary (Other than the 3 subsidiaries stated in para 5 above) whose financial statements reflect total revenue from operations of Rs. Nil, total comprehensive income after tax of Rs.(-) 20.84 Lakhs for the quarter ended June 30, 2025 as considered in the unaudited consolidated financial statements.

We also did not review the Group's share of net Profit / loss (after tax) of Rs.119.94 Lakhs of the associate for the quarter ended June 30, 2025, as considered in the unaudited consolidated financial statements.



The financial information of the subsidiary and associate are unaudited and have been furnished to us by the management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and associate, is based solely on such unaudited financial results.

Our Conclusion is not modified in respect of the above matters.

9. The figures for the quarter ended March 31, 2025 as reported in the Statement is the balancing figures between audited figures in respect of the full financial year ended on March 31, 2025 and the published year to date figures upto the end of the third quarter ended December 31, 2024. Also, the figures up to the end of the third quarter had only been reviewed by us as required under the Listing Regulations and not subjected to audit. Our Conclusion is not modified in respect of this matter.



Place: Mumbai

Date: August 12, 2025

For Singhi & Co.,
Chartered Accountants
Firm Regn. No. 302049E

A handwritten signature in blue ink, appearing to read 'Sudesh Choraria', written over a light-colored rectangular background.

Sudesh Choraria
Partner
Membership No.204936
UDIN: 25204936BMIPCH8275